Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. GPCR
GPCR logo

GPCR News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

GPCR News

Casdin Capital Reduces Stake in Structure Therapeutics

Feb 27 2026Fool

Structure Therapeutics Reports Q4 Net Income of $33 Million

Feb 26 2026seekingalpha

BVF Increases Stake in Structure Therapeutics with $11.2 Million Purchase

Feb 25 2026Fool

Eli Lilly's Dominance in Obesity Drug Market Reinforced

Feb 23 2026CNBC

Rock Springs Capital Reduces Stake in Structure Therapeutics

Feb 17 2026Fool

Structure Therapeutics' GLP-1 Drug Shows Promising Potential

Feb 05 2026Fool

Structure Therapeutics Emerges as Potential Takeover Target for Big Pharma

Jan 30 2026seekingalpha

Structure Therapeutics Advances Aleniglipron into Phase 3 Trials Following Novo Nordisk's Oral GLP-1 Launch

Jan 23 2026Benzinga

GPCR Events

01/30 12:00
Major Averages Broadly Lower as Tech Stocks Decline
The major averages were broadly lower near noon as tech stocks continue to decline and as investors continue to analyze earnings, monetary policy news, and macroeconomic data. On the macro side, markets are digesting the implications of the nomination of Kevin Warsh as the next Federal Reserve Chair. Warsh's nomination has lifted the U.S. dollar and pressured commodities like gold and silver, while traders recalibrate expectations for interest rates and policy continuity. At the same time, the upcoming week's heavy slate of earnings and labor market data looms as a catalyst for direction in equities.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:President Trump has nominatedApplereportedand provided Q2 revenue guidanceChevronand Exxon Mobilboth reportedVerizonreportedand authorized a $25B share repurchase programAmerican Expressand Visaboth reported2. WALL STREET CALLS:HSBCPinterestto Hold on softer near-term outlookSanDiskto Outperform at Raymond JamesCodere Onlineto Hold at StifelSpotifyto Buy at CitiSouthwestto Outperform at BMO Capital3. AROUND THE WEB:Alibabaand ByteDance both plan to release flagship AI models around China's mid-February Lunar New Year holiday, including ByteDance's Doubao 2.0, The Information saysAccording to new NHTSA crash data and Tesla'snew disclosure of Robotaxi mileage, Tesla's driverless vehicles are crashing at a much higher rate than human drivers, even with a safety monitor in every vehicle, Electrek reportsGameStopshares have dropped 80% since becoming a meme stock in 2021, but GameStop CEO Ryan Cohen plans to turn the $11B company into a $100B juggernaut, WSJ saysNvidiaassisted China's DeepSeek with refining its AI models that were later used in the Chinese military, Reuters reportsStructure Therapeutics, which his working on next-gen oral obesity medication, has emerged as the next top M&A target for Big Pharma, Axios says4. MOVERS:Robert Halfgains afterand provided guidance for Q1Deckers Outdoorincreases afterand raising its guidance for FY26Critical Metals (CRML) lower in New York afterto fast track the development of its Tanbreez projectLexiconfalls after announcing aPennyMac Financiallower after5. EARNINGS/GUIDANCESoFi Technologiesand provided guidance for Q1 and FY26GCL Globalresults and cut its guidance for FY26Church & Dwight, with CEO Rick Dierker commenting, "we are pleased to deliver another year of industry-leading results"Colgate-Palmolive, with EPS and revenue beating consensusAon plc, with CEO Greg Case commenting, "Our fourth-quarter and full-year results reflect the strong execution of our 3x3 Plan, accelerating our client-centric Aon United strategy"INDEXES:Near midday, the Dow was down 0.84%, or 414.43, to 48,657.13, the Nasdaq was down 0.64%, or 151.85, to 23,533.28, and the S&P 500 was down 0.51%, or 35.80, to 6,933.21.
01/30 10:50
Structure Therapeutics Emerges as Next M&A Target for Big Pharma
Structure Therapeutics, which his working on next-gen oral obesity medication, has emerged as the next top M&A target for Big Pharma, Axios' Katherine Davis reports. The new market for obesity drugs has reshaped dealmaking in biopharma, as big companies look to replace expiring patents and buy into the fast-growing business, the author notes.

GPCR Monitor News

Structure Therapeutics seen as potential acquisition target amid market decline

Feb 03 2026

Structure Therapeutics Reports Positive Phase 2 Data for Aleniglipron

Jan 14 2026

Structure Therapeutics Reports Positive Phase 2 Data for Aleniglipron

Jan 13 2026

Structure Therapeutics Inc. rises on market strength

Dec 23 2025

Structure Therapeutics Inc Hits 52-Week High on Positive Trial Data

Dec 08 2025

GPCR Hits 52-Week High Amid Positive Analyst Outlook

Nov 19 2025

GPCR.O Surges Past 5-Day SMA Amid Positive Sentiment

Nov 14 2025

GPCR Earnings Analysis

No Data

No Data

People Also Watch